keyword
MENU ▼
Read by QxMD icon Read
search

Nivolumab renal cell carcinoma

keyword
https://www.readbyqxmd.com/read/29784745/updates-to-the-management-of-kidney-cancer
#1
Eric Jonasch
Several updates were made to the 2018 NCCN Guidelines for Kidney Cancer. Adjuvant sunitinib is the first adjuvant therapy to be endorsed by the panel for patients with stage II and III clear cell histology renal cell carcinoma (RCC; category 2B). A promising new treatment-ipilimumab plus nivolumab for patients at intermediate and poor risk in the frontline setting-was added to the guidelines as well. Cabozantinib was added as a first-line option for poor- and intermediate-risk patients with advanced RCC.
May 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29782188/an-evaluation-of-nivolumab-for-the-treatment-of-metastatic-renal-cell-carcinoma
#2
Kevin Zarrabi, Shenhong Wu
The treatment paradigm for metastatic renal cell carcinoma (mRCC) has undergone a revolution with the rapid market approval of multiple agents over a three-year period. The immunogenicity of RCC provided the biological rationale to assess the clinical efficacy of nivolumab, an immune checkpoint inhibitor. Nivolumab is approved for second-line treatment after failure of angiogenesis targeted therapy and in combination therapy with ipilimumab for previously untreated intermediate or poor-risk advanced renal cell carcinoma...
May 21, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29774766/negative-prognostic-factors-and-resulting-clinical-outcome-in-patients-with-metastatic-renal-cell-carcinoma-included-in-the-italian-nivolumab-expanded-access-program
#3
Sergio Bracarda, Luca Galli, Marco Maruzzo, Giovanni Lo Re, Sebastiano Buti, Adolfo Favaretto, Francesco Di Costanzo, Cosimo Sacco, Marco Merlano, Claudia Mucciarini, Elena Zafarana, Sante Romito, Antonio Maestri, Carmelo G Giorgio, Maria T Ionta, Daniele Turci, Ugo De Giorgi, Giuseppe Procopio, Enrico Cortesi, Diana Giannarelli, Camillo Porta
AIM: We report the outcomes observed with nivolumab in metastatic renal cell carcinoma patients with poor prognostic features enrolled in the Italian expanded access program. PATIENTS & METHODS: Nivolumab was available for patients who relapsed after at least one prior systemic treatment in the advanced or metastatic setting. RESULTS: Of 389 patients, 32 (8%) had brain metastasis, 129 (33%) had liver and 193 (50%) had bone metastasis. These subpopulations achieved a disease control rate of 53, 45 and 47%, respectively...
May 18, 2018: Future Oncology
https://www.readbyqxmd.com/read/29728867/check-point-inhibitors-a-new-era-in-renal-cell-carcinoma-treatment
#4
REVIEW
Mohamed Alsharedi, Heather Katz
In the United States, the estimated number of new cases of renal cell carcinoma (RCC) is approximately 65,000 case with about 15,000 deaths in the year of 2018 (Siegel et al. in CA Cancer J Clin 68(1):7, 2018). RCC as an immunogenic malignancy is supported by many theories and facts which include tumor richness of lymphocytes infiltrate, the occurrence of spontaneous tumor regression, and the proved effect of traditional immunotherapy (Finke et al. in J Immunother 11(1):1-11, 1992), all these factors support the potential therapeutic effect of the novel immunotherapeutic agents in RCC...
May 4, 2018: Medical Oncology
https://www.readbyqxmd.com/read/29728723/pushing-the-limits-of-immune-related-response-a-case-of-extreme-pseudoprogression
#5
Alvin S Wong, Yee-Liang Thian, Jeevesh Kapur, Cheng-Nang Leong, Patrick Kee, Chun-Tsu Lee, Martin B Lee
The advent of immune checkpoint targeted immunotherapy has seen a spectrum of immune-related phenomena in both tumor responses and toxicities. We describe a case of pseudoprogression that pushes the limits of immune-related response criteria and challenges the boundaries and definitions set by trial protocols. A middle-aged man with conventional clear cell renal cell carcinoma (RCC) had received multiple prior systemic treatments including vascular endothelial growth factor receptor tyrosine kinase inhibitors, as well as multiple surgeries and radiotherapy treatments...
May 4, 2018: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/29727313/nivolumab-in-the-treatment-of-metastatic-renal-cell-carcinoma-a-cost-utility-analysis
#6
Jacques Raphael, Zhuolu Sun, Georg A Bjarnason, Joelle Helou, Beate Sander, David M Naimark
INTRODUCTION: Nivolumab improves overall survival and health-related quality of life compared with everolimus in metastatic renal cell carcinoma (mRCC). This study assesses the cost-utility of nivolumab from the Canadian health care payer perspective. MATERIALS AND METHODS: To evaluate the cost-utility of nivolumab, a Markov cohort model that incorporated data from the phase 3 CheckMate-025 trial and other sources was developed. The incremental cost per quality-adjusted life month (QALM) gained for nivolumab was calculated...
May 4, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29726696/systematic-review-on-the-efficacy-and-safety-of-immune-checkpoint-inhibition-in-renal-cell-carcinoma
#7
Chen Lyu, Wenyue Li, Songcai Liu, Shuang Gao, Hong Zhang, Linlin Hao, Hao Yu, Wenzhen Wei, Jie Song, Yaoyao Yang, Chunmeng Wang, Zhimin Zhang, Nan Wang
To perform a systematic review of the relevant literature about clinical trials on efficacy and safety of immune checkpoint inhibition, whether it is used alone, in combination or with other targeted therapies in patients with advanced and metastatic renal cell carcinoma (RCC), two team members reviewed the abstracts and selected pertinent articles from the relevant databases. A narrative review of randomized controlled trials was performed and seven randomized controlled trials were identified in this systematic review...
May 4, 2018: Future Oncology
https://www.readbyqxmd.com/read/29719414/cost-effectiveness-comparison-of-cabozantinib-with-everolimus-axitinib-and-nivolumab-in-the-treatment-of-advanced-renal-cell-carcinoma-following-the-failure-of-prior-therapy-in-england
#8
Jie Meng, Johanna Lister, Anne-Lise Vataire, Roman Casciano, Jerome Dinet
Purpose: The aim of this study was to compare the cost-effectiveness of cabozantinib with the standard of care in England in adult patients with advanced renal cell carcinoma (aRCC), following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy. Methods: We developed a partitioned-survival model with three health states to assess the cost-effectiveness of cabozantinib and its comparators. The model time horizon was 30 years. Efficacy and safety data were derived from pivotal clinical trials (METEOR: NCT01865747, CheckMate025: NCT01668784, and AXIS: NCT00678392)...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/29708353/-treatment-of-metastatic-renal-cell-carcinoma
#9
Igor Richter, Josef Dvořák
INTRODUCTION: Renal cell cancer accounts for approximately 2-3% of all cases of malignancy. The incidence of kidney cancer in the Czech Republic is the highest in the world. Approximately 70% of renal cell carcinomas are clear-cell renal cancer. Various treatment options for metastatic renal cell cancer (mRCC) have been developed. Treatment regimens comprise antiangiogenic drugs in combination with vascular endothelial growth factor receptor inhibitors, mTOR inhibitors, and immunotherapy...
2018: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
https://www.readbyqxmd.com/read/29706304/renal-cell-carcinoma-brain-metastasis-with-pseudoprogression-and-radiation-necrosis-on-nivolumab-after-previous-treatment-with-stereotactic-radiosurgery-an-illustrative-case-report-and-review-of-the-literature
#10
Gary D Lewis, Eric Jonasch, Amishix Y Shah, Gregory N Fuller, Andrew M Farach, E Brian Butler, Bin S Teh
No abstract text is available yet for this article.
March 10, 2018: Practical Radiation Oncology
https://www.readbyqxmd.com/read/29693280/case-of-complete-response-to-neoadjuvant-therapy-using-nivolumab-in-a-patient-with-metastatic-renal-cell-carcinoma
#11
Daiki Ikarashi, Yoichiro Kato, Hirokatsu Katagiri, Takeshi Takahara, Noriyuki Uesugi, Ei Shiomi, Jun Sugimura, Hiroyuki Nitta, Tamotsu Sugai, Wataru Obara
Here, we report a case of a 68-year-old woman with cT4N0M1 (liver invasion and multiple lung metastases) metastatic renal cell carcinoma. We could carry out less invasive nephrectomy with partial hepatectomy because nivolumab administration as second-line therapy reduced the primary tumor remarkably. To the best of our knowledge, this is the first report of the use of nivolumab before carrying out surgery, and histological findings showed a pathological complete response.
April 25, 2018: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/29680230/percutaneous-ablative-cryoimmunotherapy-for-micrometastaic-abscopal-effect-no-complications
#12
Erik Soule, Mark Bandyk, Jerry Matteo
Recent studies have shown efficacy of nivolumab, a monoclonal antibody specific for an immunoregulatory protein termed programmed death 1 (PD-1), against metastatic renal cell carcinoma. PD-1 is a transmembrane protein expressed on T cells that suppresses activation upon binding to its ligands, which may be secreted paraneoplastically by various cancers. Inhibition of PD-1 signaling via nivolumab may sensitize tumor-specific T lymphocytes in the immunosuppressive tumor microenvironment. Systemic elimination of micrometastases requires robust activation and proliferation of tumor antigen stimulated T cells...
April 19, 2018: Cryobiology
https://www.readbyqxmd.com/read/29669553/significant-response-to-nivolumab-for-metastatic-chromophobe-renal-cell-carcinoma-with-sarcomatoid-differentiation-a-case-report
#13
Go Noguchi, Sohgo Tsutsumi, Masato Yasui, Shinji Ohtake, Susumu Umemoto, Noboru Nakaigawa, Masahiro Yao, Takeshi Kishida
BACKGROUND: The treatment of advanced or metastatic renal cell carcinoma (RCC) has drastically changed since the approval of immune checkpoint therapy. Nivolumab is a treatment option for patients with metastatic RCC, previously treated with targeted antiangiogenic therapy. The efficacy of nivolumab for patients with RCC was established by the Checkmate 025 clinical trial. Chromophobe RCC (CRCC) represents around 5% of RCC cases, but non-clear cell RCC (non-ccRCC) subtypes were excluded from the Checkmate 025 clinical trial...
April 18, 2018: BMC Urology
https://www.readbyqxmd.com/read/29663063/-treatment-with-pd-1-pd-l1-and-ctla-4-immune-checkpoint-inhibitors-immune-mediated-side-effects
#14
REVIEW
M-O Grimm, H Oppel-Heuchel, S Foller
Immune checkpoint inhibitors are a new standard therapy for advanced or metastatic urothelial as well as renal cell carcinoma. Atezolizumab and Pembrolizumab have been approved for the treatment of cisplatin-ineligible patients with transitional call cancer in the 1st line setting; both antibodies and Nivolumab may also be used after platinum based prior therapy. Regarding renal cell carcinoma approval for 1st line treatment with the combination of Nivolumab and Ipilimumab for patients at intermediate or high risk (IMDC) is currently expected...
May 2018: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/29662541/cabozantinib-in-the-treatment-of-advanced-renal-cell-carcinoma-in-adults-following-prior-vascular-endothelial-growth-factor-targeted-therapy-clinical-trial-evidence-and-experience
#15
REVIEW
Susanne Osanto, Tom van der Hulle
Cabozantinib is an oral multitargeted tyrosine kinase inhibitor (TKI) that potently inhibits MET and AXL, both associated with poor prognosis in renal cell carcinoma (RCC), next to vascular endothelial growth factor receptor 2, KIT, FLT3 and RET. Chronic treatment with vascular endothelial growth factor receptor (VEGFR)-targeting sunitinib upregulates MET and AXL in RCC, indicating that cabozantinib may be particularly effective in patients with advanced RCC whose disease progressed on prior VEGFR-targeted treatment...
March 2018: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/29656851/first-line-systemic-therapy-for-metastatic-renal-cell-carcinoma-a-systematic-review-and-network-meta-analysis
#16
REVIEW
Christopher J D Wallis, Zachary Klaassen, Bimal Bhindi, Xiang Y Ye, Thenappan Chandrasekar, Ann M Farrell, Hanan Goldberg, Stephen A Boorjian, Bradley Leibovich, Girish S Kulkarni, Prakesh S Shah, Georg A Bjarnason, Daniel Heng, Raj Satkunasivam, Antonio Finelli
CONTEXT: In the last decade, there has been a proliferation of treatment options for metastatic renal cell carcinoma (mRCC). However, direct comparative data are lacking for most of these agents. OBJECTIVE: To indirectly compare the efficacy and safety of systemic therapies used in the first-line treatment of mRCC. EVIDENCE ACQUISITION: Medline, EMBASE, Web of Science, and Scopus databases were searched using the OvidSP platform for studies indexed from database inception to October 23, 2017...
April 13, 2018: European Urology
https://www.readbyqxmd.com/read/29623210/new-onset-insulin-dependent-diabetes-due-to-nivolumab
#17
Ali A Zaied, Halis K Akturk, Richard W Joseph, Augustine S Lee
Nivolumab, a monoclonal antibody against programmed cell death-1 receptor, is increasingly used in advanced cancers. While nivolumab use enhances cancer therapy, it is associated with increased immune-related adverse events. We describe an elderly man who presented in ketoacidosis after receiving nivolumab for metastatic renal cell carcinoma. On presentation, he was hyperpneic and laboratory analyses showed hyperglycemia and anion-gapped metabolic acidosis consistent with diabetic ketoacidosis. No other precipitating factors, besides nivolumab, were identified...
2018: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/29606588/nivolumab-plus-ipilimumab-in-advanced-renal-cell-carcinoma
#18
Ashray Gunjur
No abstract text is available yet for this article.
March 29, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29593922/nivolumab-induced-encephalitis-in-hereditary-leiomyomatosis-and-renal-cell-cancer-syndrome
#19
Benjamin Chaucer, Abriella Stone, Augustus Demanes, Shawn M Seibert
The treatment of cancer is a rapidly evolving field. As more chemotherapeutic agents become available, reporting the side effects of these agents in clinical practice becomes increasingly important. Nivolumab is one of the chemotherapeutic agents commonly used for treatment of renal cell carcinoma, metastatic melanoma, and metastatic non-small cell lung cancer. While common side effects are known and well documented, encephalitis is documented as an extremely rare side effect. We present the case of an extremely rare side effect to a common chemotherapeutic agent...
2018: Case Reports in Oncological Medicine
https://www.readbyqxmd.com/read/29587324/-immunotherapy-for-renal-cell-carcinoma-current-status
#20
Marc-Oliver Grimm, Susan Foller
Systemic treatment of metastatic renal cell carcinoma (mRCC) has substantially changed during the last 2 years due to approval of the immune-checkpoint inhibitor Nivolumab (Opdivo® ) and new multikinase inhibitors (Cabozantinib, Lenvatinib, Tivozanib). The german kidney tumor guideline strongly recommends Nivolumab and Cabozantinib as 2nd line treatments after prior VEGF targeted therapy. CheckMate 025, the prospective randomized trial which led to approval of Nivolumab demonstrated improved overall survival (26 month vs...
April 2018: Aktuelle Urologie
keyword
keyword
110016
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"